CLRB Cellectar Biosciences, Inc.

1.76
0  -6%
Previous Close 1.87
Open 1.93
Price To book 1.53
Market Cap 22.59M
Shares 12,837,000
Volume 422,953
Short Ratio 1.46
Av. Daily Volume 576,594

SEC filingsSee all SEC filings

  1. 8-K - Current report 17788960
  2. DEF 14A - Other definitive proxy statements 17781112
  3. 8-K - Current report 17781104
  4. 8-K - Current report 17776611
  5. 8-K - Current report 17767034

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced March 30, 2017. Initial data due 2H 2017.
CLR 131
Various lymphoma

Latest News

  1. Cellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies
  2. Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers
  3. UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
  4. Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells
  5. Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
  6. Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors
  7. After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
  8. Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC
  9. Edited Transcript of CLRB earnings conference call or presentation 15-Mar-17 10:00pm GMT
  10. Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017
  11. Cellectar Biosciences Secures Japanese Patent
  12. Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio
  13. Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance
  14. Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement
  15. Cellectar Biosciences to Present at 29th Annual Roth Conference
  16. Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months
  17. Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma
  18. Cellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma
  19. UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference
  20. Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

SEC Filings

  1. 8-K - Current report 17788960
  2. DEF 14A - Other definitive proxy statements 17781112
  3. 8-K - Current report 17781104
  4. 8-K - Current report 17776611
  5. 8-K - Current report 17767034
  6. PRE 14A - Other preliminary proxy statements 17762905
  7. 8-K - Current report 17754911
  8. 8-K - Current report 17725648
  9. 8-K - Current report 17704245
  10. 8-K - Current report 17692940